Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)

ClinicalTrials.gov ID: NCT00617019

Public ClinicalTrials.gov record NCT00617019. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 25, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Cross-sectional, Retrospective Screening and Case-control Study Examining the Frequency of, and Risk Factors Associated With, Impulse Control Disorders in Parkinson's Disease Patients Treated With MIRAPEX® (Pramipexole) and Other Anti-parkinson Agents (DOMINION Study)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose is to explore the frequency of impulse control disorders in Parkinson's patients treated with different Parkinson's medications.

Study identification

NCT ID
NCT00617019
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
3,234 participants

Conditions and interventions

Interventions

Not listed

Eligibility (public fields only)

Age range
30 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2006
Primary completion
Dec 31, 2007
Completion
Not listed
Last update posted
Nov 12, 2013

Started 2006

United States locations

U.S. sites
36
U.S. states
20
U.S. cities
34
Facility City State ZIP Site status
248.619.01034 Neurological Physicians of Arizona Gilbert Arizona — —
248.619.01007 Mayo Clinic - Scottsdale Scottsdale Arizona — —
248.619.01025 Sun Health Research Institute Sun City Arizona — —
248.619.01018 Margolin Brain Institute Fresno California — —
248.619.01031 Pacific Neuroscience Medical Group, Inc. Oxnard California — —
248.619.01016 San Francisco VA PD Research, Education, & Clinical Center San Francisco California — —
248.619.01023 The Parkinson's Institute Sunnyvale California — —
248.619.01021 Boehringer Ingelheim Investigational Site Englewood Colorado — —
248.619.01027 Associated Neurologists, P.C. Danbury Connecticut — —
248.619.01013 Molecular NeuroImaging New Haven Connecticut — —
248.619.01020 Parkinson's Disease and Movement Disorders of Boca Raton Boca Raton Florida — —
248.619.01009 University of Florida Gainesville Florida — —
248.619.01035 Emory University Atlanta Georgia — —
248.619.01006 Medical College of Georgia Augusta Georgia — —
248.619.01014 Northwestern University Chicago Illinois — —
248.619.01001 The University of Kansas Medical Center Kansas City Kansas — —
248.619.01015 John Hopkins Hospital Baltimore Maryland — —
248.619.01029 Clinical Neuroscience Center Southfield Michigan — —
248.619.01022 University of Minnesota Minneapolis Minnesota — —
248.619.01008 Robert Wood Johnson Medical School Piscataway New Jersey — —
248.619.01030 Parkinson's Disease and Movement Disorders Center Albany New York — —
248.619.01036 Parkinson's Disease and Mov. Disorders Center of Long Island Commack New York — —
248.619.01017 Weill Cornell medical College New York New York — —
248.619.01003 Duke University Medical Center Durham North Carolina — —
248.619.01028 The Cleveland Clinic Foundation Cleveland Ohio — —
248.619.01004 Lehigh Valley Hospital Allentown Pennsylvania — —
248.619.01010 Parkinson's Disease research, Education and Clinical Center Philadelphia Pennsylvania — —
248.619.01011 University of Pennsylvania Philadelphia Pennsylvania — —
248.619.01024 Thomas Jefferson Hospital Philadelphia Pennsylvania — —
248.619.01019 Boehringer Ingelheim Investigational Site Pittsburgh Pennsylvania — —
248.619.01012 Parkinson's Disease and Movement Disorders Center Upland Pennsylvania — —
248.619.01005 NeuroHealth Warwick Rhode Island — —
248.619.01033 Vanderbilt University Medical Center Nashville Tennessee — —
248.619.01032 Neurology Spclst of Dallas, PA Dallas Texas — —
248.619.01002 Baylor College of Medicine Houston Texas — —
248.619.01026 Neurology/Southeast Parkinson's Disease Richmond Virginia — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00617019, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 12, 2013 · Synced Sep 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00617019 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →